Close Sidebar
Nordic Life Science
Now Reading
LIDDS’s Nanozolid registered in the US
Search for content, post, videos
Search for content, post, videos
Advertisement

LIDDS’s Nanozolid registered in the US

January 23, 2020
1610 Views
Monica Wallter

LIDDS has announced that the United States Patent and Trademark Office has registered the trademark NanoZolid.

LIDDS thereby has exclusive rights to the trademark for products and services in the USA and in the EU, where NanoZolid has been registered since 2016.

“This is an essential, although expected, step in establishing the concept of LIDDS proprietary drug delivery technology NanoZolid for local depots and adds to our already strong IP portfolio,” confirms LIDDS CEO Monica Wallter.

Advertisement

Photo of Monica Wallter: LIDDS

Related Posts

Alex Karlsson Parra
February 7, 2020

Immunicum has announced updated results from the randomized Phase II MERECA trial testing its off-the-shelf immune primer ilixadencel in combination with Sutent (sunitinib) first-line treatment regimen in newly diagnosed metastatic renal cell carcinoma (mRCC) patients. December 2019 data confirm the separation in survival curves in favor of the ilixadencel group…

September 5, 2014

Meda has signed an agreement to divest the manufacturing unit in Lakewood, New Jersey. The manufacturing unit will be divested to the contract manufacturer DPT. According to Meda the manufacturing facility is dedicated to global supply of the product MUSE. As part of the agreement Meda has entered into a long…

uppsala
October 19, 2016

Recipharm has announced a 5 million SEK investment into a new GLP (Good Laboratory Practice) compliant bioanalysis laboratory at its development facility in Uppsala, Sweden, in response to growing customer demand. The investment will see the opening of a 500 square metre purpose-built facility in November 2016, which will become the…

Marcus Schindler
January 8, 2024

The Omega collaboration will leverage its platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management. The Cellarity collaboration aims to unravel novel biological drivers of MASH and will leverage Cellarity’s platform to develop a small…